NewsBenzingaSagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11 Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11 Benzinga 2026.10.09 11:15 (GMT+0) Open on Benzinga Other news Sell Eagle Point Credit Now – Match The Loss With Portfolio Gains To Lower Income Taxes 3 Bear Put Spread Trade Ideas For This Monday What to Expect From Coherent's Next Quarterly Earnings Report Netflix Stock Might be a Sleeper Hit 'Europe’s Top Carriers Explore Satellite Group to Fend Off SpaceX' - Bloomberg HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target
